1
|
Bruno F, Pellerino A, Pronello E, Bertero L, Tampieri C, Francia Di Celle P, Mantovani C, Moro M, Bartoletti V, Baciorri F, Garbossa D, Soffietti R, Rudà R. JS06.4.A Intracranial ependymomas of the adult: outcome and response to treatments across molecular subtypes. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The 2021 WHO Classification lists two molecularly defined types of supratentorial ependymomas (STEs), i.e., ZFTA and YAP1 fusions, and posterior fossa ependymomas (PFEs), i.e, PFA and PFB. Based on retrospective data, the presence of the ZFTA fusion (for STEs) and the PFA subtype (for PFEs) seem to correlate with a poorer outcome. However, prospective data on large cohorts of adult patients are lacking, and the role of treatments is uncertain. The aim of our study is to investigate the clinical characteristics, response to treatment, and outcome of a cohort of adult patients with supratentorial and posterior fossa ependymomas across different molecular subtypes.
Patients and Methods
Clinical data of patients ≥18 years with STEs and PFEs were retrospectively collected from 2 Italian Centres (Turin, Treviso). ZFTA and YAP1 fusions were detected by FISH, while PFA and PFB subtypes were defined by anti-H3K27me3 immunohistochemistry.
Results
We collected 42 adult patients with STEs (11, 26.2%) and PFEs (31, 73.8%) diagnosed between 1984 and 2021. Median age was 45 years. ZFTA and YAP1 fusions were found in 5 (45.5%) and 1 (9.1%) case of STEs. PFA and PFB subtypes accounted for 9 (29.0%) and 22 (71.0%) cases of PFEs. Extent of resection (EOR) was gross-total (GTR) in 6/11 (54.8%) STEs and 17/31 PFEs (54.8%). 4/11 (36.4%) STEs and 9/31 (29.0%) PFEs received adjuvant radiotherapy (RT). Median progression-free survival (mPFS) and overall survival (mOS) were 172 and 61.6 months for STEs patients, and not reached (NR) and 332 months for PFEs. For patients with STEs, the presence of ZFTA fusion correlated with a significant shorter PFS (64.0 months vs NR, p = 0.05) and with a trend for shorter mOS (168.0 months vs NR, p = 0.307). The only patient with YAP1 fusion had a very long PFS (33 years). In a multivariable analysis, EOR and adjuvant RT did not significantly affect survival of STEs patients.For patients with PFEs, PFA and PFB subtypes did not differ significantly in terms of mPFS (NR vs 137.0 months, p = 0.513) and mOS (NR vs NR, p = 0.132). Conversely, GTR was associated with a significantly longer mPFS (NR vs 63.0 months, p = 0.007) and with a trend for longer mOS (NR vs 332.0 months, p = 0.146). In a multivariable analysis, GTR was associated with a significantly lower risk of disease progression, both in the entire cohort of PFE patients (p = 0.016), and within the PFA subtype (p = 0.013). Similarly, GTR was associated with a trend for better PFS within the PFB subtype.
Conclusion
Our preliminary data on a real-life cohort of adult patients confirm the worse prognosis of STEs harbouring the ZFTA fusion and suggest an impact of the EOR among PFEs regardless of molecular subtypes. Larger populations of patients are needed to better define the role of treatment modalities within molecular subrogups. The study is still ongoing in a multicentric setting.
Collapse
Affiliation(s)
- F Bruno
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - A Pellerino
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - E Pronello
- Neurology Unit, Dept. of Translational Medicine, University of Eastern Piedmont, Novara, Italy , Novara , Italy
| | - L Bertero
- Pathology Unit, Dept. of Medical Sciences, University of Turin, Turin, Italy , Turin , Italy
| | - C Tampieri
- Pathology Unit, Dept. of Medical Sciences, University of Turin, Turin, Italy , Turin , Italy
| | - P Francia Di Celle
- Molecular Pathology Unit, Dept. of Medical Sciences, Turin, Italy , Turin , Italy
| | - C Mantovani
- Division of Radiotherapy, Dept. of Oncology, University and City of Health and Science, Turin, Italy , Turin , Italy
| | - M Moro
- Dept. of Neurosurgery, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy , Treviso , Italy
| | - V Bartoletti
- Dept. of Neurosurgery, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy , Treviso , Italy
| | - F Baciorri
- Dept. of Pathology, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy , Turin , Italy
| | - D Garbossa
- Division of Neurosurgery, Dept. of Neuroscience, University and City of Health and Science, Turin, Italy , Turin , Italy
| | - R Soffietti
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - R Rudà
- University and City of Health and Science, Turin, Italy , Turin , Italy
- Dept. of Neurology, Castelfranco and Treviso Hospitals, Italy , Treviso , Italy
| |
Collapse
|
2
|
Pellerino A, Bruno F, D'Alessandris QG, Internò V, Polo V, Pronello E, Somma T, Spena G, Ius T, Esposito V, Rudà R. P11.59.B Real-life application of the 2021 WHO Classification molecular criteria in Italy: a national survey from the Italian Association of Neuro-Oncology (AINO) Gruppo Giovani. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Diffuse gliomas display heterogeneous biology, natural history, response to treatments, and outcome. According to the 2021 WHO Classification, an integration of histological and molecular factors is needed for the diagnosis of diffuse gliomas. The Italian Association of Neuro-Oncology (AINO), with the participation of the Italian Society of Neurosurgery (SINch), promoted a survey to explore how the 2021 WHO molecular diagnostic criteria are integrated into clinical practice in a national framework.
Material and Methods
A web-based survey containing 38-item multiple-choice questions was sent to members of the AINO and SINch in February 2022 via the respective email listings of these organizations.
Results
We collected 152 answers. Most attendants were < 45-year-old (117, 77.0%). Participants from North, Centre and South of Italy were 85 (55.9%), 38 (25.0%), and 29 (19.1%). Academic and non-academic hospitals were 35 (46.1%) and 82 (53.9%). The presence of an institutional Brain Tumour Board was reported in 108 cases (71.7%). One hundred forty attendees (92.1%) reported that IDH mutation was assessed in all glioma patients regardless of age. The 1p19q-codeletion was assessed routinely in all IDH-mutant gliomas in 88 (57.9%) or when TP53 mutation and/or ATRX expression was found (45, 29.6%). The MGMTp methylation was assessed, regardless of grading, at diagnosis in 110 (72.4%), and at second surgery in 82 (53.9%). Eighty (52.6%) performed a quantitative analysis of MGMTp status. The CDKN2A/B homozygous deletion in IDH-mutant lower-grade astrocytomas was routinely investigated in 53 (34.9%). Assessment of EGFR amplification, pTERT status or +7/-10 chromosome alterations to stratify IDH-wildtype lower-grade astrocytomas was reported in 76 (50.0%), 43 (28.3%), and 16 (10.5%) cases. Rarer alterations were less commonly investigated (H3K27M: 34, 22.4%; H3G34: 11, 7.2%; BRAF: 18, 11.8%; NTRK: 16, 10.5%), being usually evaluated in selected cases (e.g., younger patients). Academic vs non-academic hospitals treated more patients per year (> 300 in 22/70, 31.4% vs 3/82, 3.7%, p<0.001), had more available molecular technologies (53/70, 75.5% vs 37/82, 45.1, p<0.001), had a higher availability of molecular markers, such as CDKN2A/B deletion (34/70, 48.6% vs 19/82, 23.2%, p=0.001), MGMTp at second surgery (48/69, 69.6% vs 34/72, 47.2%, p=0.008), EGFR/pTERT/+7-10 (46/70, 65.7% vs 32/77, 41.6%, p=0.003), BRAF (14/70, 20.0% vs 4/82, 4.9%, p=0.002), NTRK (14/70, 20.0% vs 2/81, 2.5%, p<0.001).
Conclusion
The availability of new molecular markers is increasing among Italian Neuro-Oncology Centres. However, there is still a gap with the proposed criteria of the 2021 WHO Classification and the real-life application. A critical issue remains how to select patients who might benefit from the identification of some extremely rare mutations in light of targeted therapies.
Collapse
Affiliation(s)
- A Pellerino
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - F Bruno
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - Q G D'Alessandris
- UOC Neurochirurgia, Fondazione Policlinico Universitario A. Gemelli IRCCS , Roma , Italy
| | - V Internò
- Department of Interdisciplinary Medicine, Policlinico Hospital and University "Aldo Moro" , Bari , Italy
| | - V Polo
- Department of Neurology, Castelfranco Veneto/Treviso Hospital , Treviso , Italy
| | - E Pronello
- Department of Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont , Novara , Italy
| | - T Somma
- Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Università degli Studi di Napoli Federico II , Napoli , Italy
| | - G Spena
- Department of Neurosurgery, IRCCS Fondazione Policlinico San Matteo , Pavia , Italy
| | - T Ius
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital , Udine , Italy
| | - V Esposito
- Department of Neurosurgery, IRCCS Neuromed, Pozzilli , Isernia , Italy
- Sapienza University , Roma , Italy
| | - R Rudà
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
- Department of Neurology, Castelfranco Veneto/Treviso Hospital , Treviso , Italy
| |
Collapse
|
3
|
Bruno F, Pellerino A, Pronello E, Palmiero R, Polo V, Vitaliani R, Trincia E, Internò V, Porta C, Soffietti R, Rudà R. OS07.4.A Regorafenib in recurrent glioblastoma patients: a multicentric real-life study. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Few options are still available for recurrent glioblastoma (GBM). In the Italian phase 2 REGOMA trial, regorafenib improved overall survival, as compared to lomustine, for GBM patients at first progression after chemoradiation. Here, we present the results of a real-life multicentre study that analysed clinical and radiological features, response to treatments, tolerability, and outcome of a cohort of GBM patients treated with regorafenib at first tumour progression.
Patients and Methods
We enrolled GBM patients at first tumour progression in three Italian Institutions (Turin, Treviso, Bari). Regorafenib was administered following an escalation dose protocol (1st cycle: 80 mg/day for 2 weeks, then 120 mg/day for one week; 2nd cycle: 120 mg/day for 2 weeks, then 160 mg/day for one week; 160 mg/day from the 3rd cycle). MRI scans were obtained at baseline and every 3 months. Progression-free survival (PFS) and overall survival (OS) were defined as time from regorafenib initiation and disease progression or death.
Results
From January 2020 to January 2022, 66 GBM patients were included. Median age was 60.0 years. MGMTp methylation was found in 30 patients (45.5%). First-line treatment consisted in chemoradiation in 61 (92.4%), in upfront TMZ (3, 4.5%) or RT alone followed by TMZ (2, 3.0%). Median dose was 120 mg/day 21q28 day, which was lower than that used in REGOMA trial (149 mg). Median PFS (mPFS) was 2.7 months (2.4 - 3.0 95% CI) and median OS (mOS) 7.1 months (5.4 - 8.9 95% CI). Best RANO response to regorafenib was partial response (PR) in 10 (15.1%), stable disease in 14 (21.2%), and progressive disease in 42 (63.7%) patients. All PRs were observed within the first three months of treatment. Patients who completed treatment up the 6th, 9th, and 12th cycles were 20, 3 and 2, respectively. Forty-six (69.7%) patients presented adverse events of any grade, and 21 (31.8%) grade III-IV toxicity. The most frequent adverse events were fatigue (33.3%), hand-foot syndrome (27.3%), and liver enzymes increase (15.2%). Two patients only (3.0%) interrupted regorafenib due to toxicity.In a multivariable analysis, factors significantly associated with disease progression were higher age (p = 0.035) and absence of MGMTp methylation (p = 0.024).
Conclusion
In this real-life study on 66 patients, mPFS and mOS were similar to those of the 59 patients enrolled in the regorafenib arm of REGOMA trial (2.7 vs 2.0 months; 7.1 vs 7.4 months, respectively). However, we observed a higher rate of PRs as compared to REGOMA (15% versus 3.0%). Type and severity of adverse events were similar between the two studies. Moreover, we had a lower incidence of discontinuations of regorafenib due to toxicity, maybe attributable to the lower dose intensity.We are further analysing the data of MRI-perfusion, with the aim to explore whether it can predict an early response or progression in comparison to standard MRI.
Collapse
Affiliation(s)
- F Bruno
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - A Pellerino
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - E Pronello
- Neurology Unit, Dept. of Translational Medicine, University of Eastern Piedmont, Novara, Italy , Novara , Italy
| | - R Palmiero
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - V Polo
- Multidisciplinary Brain Tumor Board, Ca’ Foncello Hospital, Treviso, Italy , Treviso , Italy
| | - R Vitaliani
- Multidisciplinary Brain Tumor Board, Ca’ Foncello Hospital, Treviso, Italy , Treviso , Italy
| | - E Trincia
- Multidisciplinary Brain Tumor Board, Ca’ Foncello Hospital, Treviso, Italy , Treviso , Italy
| | - V Internò
- Department of Interdisciplinary Medicine, University of Bari Aldo Moro. Division of Medical Oncology, Bari, Italy , Bari , Italy
| | - C Porta
- Department of Interdisciplinary Medicine, University of Bari Aldo Moro. Division of Medical Oncology, Bari, Italy , Bari , Italy
| | - R Soffietti
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - R Rudà
- University and City of Health and Science, Turin, Italy , Turin , Italy
- Multidisciplinary Brain Tumor Board, Ca’ Foncello Hospital, Treviso, Italy , Treviso , Italy
| |
Collapse
|
4
|
Pace A, Solari A, De Panfilis L, Lissoni B, Pronello E, Rudà R, Silvani A, Salmaggi A, Merli R, De Paula U, Bertocchi E, Verza M, Veronese S. P14.72 Involving patients and caregivers in the production of guidelines for palliative care in primary brain tumours: identification of intervention priorities. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Involving patients and caregivers is an important component of clinical guideline development. The three main Italian scientific associations for neurology, neuro-oncology and palliative care (SIN-AINO-SICP) recently appointed a joint task force (TF) of clinicians and researchers to develop specific guidance on palliative care of people with primary brain tumours, following the GRADE approach. To identify clinical questions meaningful to the patients and caregivers, a qualitative approach was used.
MATERIAL AND METHODS
Based on the existing literature and on consensus, the TF identified nine intervention areas, whose relevance was apprised by patients (via personal semi-structured interviews) and bereaved caregivers (via focus groups, FGs) from five tertiary neuro-oncology centres. Participants were prompted to provide their personal disease-related experience, and were asked to elicit the areas that mostly impacted their own lives. Interviews and FGMs were audio-recorded, transcribed and analysed using thematic analysis.
RESULTS
Twenty interviews and five FGs (28 caregivers) were completed between late 2020 and early 2021. Preliminary findings show that all the pre-specified areas were defined as important by participants. Most discussed topics were communication, organization and service satisfaction, cognitive and psychological issues, and advance care planning (ACP). Caregivers focused their discussions on the need for patient psychological support, difficulties experienced with symptoms control (e.g. epileptic seizures, behavioural changes), communication and organizational issues.
CONCLUSION
Participation of Italian patients with brain tumours and family caregivers was high and information-rich. All of the nine guideline intervention areas were considered important, communication, care organization, symptom control and ACP being the most discussed.
Collapse
Affiliation(s)
- A Pace
- IRCCS Regina Elena Cancer Institute, Rome, Italy
| | - A Solari
- Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - L De Panfilis
- Bioethics Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - B Lissoni
- Unit of Clinical Psychology, Niguarda Hospital, Milan, Italy
| | - E Pronello
- Department of Neuro-Oncology, City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Department of Neuro-Oncology, RomeCity of Health and Science University of Turin, Italy
| | - A Silvani
- Neuro-Oncologia Clinica, IRCC Istituto Neurologico Carlo Besta, Milan, Italy
| | - A Salmaggi
- Neurology and Stroke Unit, ASST, Lecco, Italy
| | - R Merli
- Neurosurgery Unit, ASST PGXXIII, Bergamo, Italy
| | - U De Paula
- Radiation Oncology, San Giovanni-Addolorata Hospital, Rome, Italy
| | - E Bertocchi
- Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - M Verza
- IRENE BT Patients Association, Rome, Italy
| | | |
Collapse
|
5
|
Pellerino A, Bello L, Conti Nibali M, Bruno F, Mo F, Pronello E, Franchino F, Soffietti R, Rudà R. P04.09 Patterns of care and impact on survival of first salvage therapy in high-risk grade II gliomas following initial temozolomide. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
BACKGROUND
Initial chemotherapy with temozolomide (TMZ) may provide benefit in high-risk low-grade gliomas. To date, no standard treatment is validated at first progression. The aim of this retrospective study was to investigate the optimal salvage therapy after the first progression and the factors that influence the PFS and overall survival (OS).
MATERIAL AND METHODS
we evaluated 71 patients with an histological diagnosis of grade II glioma according to WHO 2016 classification, who were included in a phase II AINO (Italian Association for Neuro-Oncology) trial, and progressed following initial chemotherapy with TMZ. Molecular data were available in all patients: 32 (45.1%) patients were oligodendrogliomas IDH 1/2 mutated and 1p19q codeleted, 11 (15.5%) were diffuse astrocytomas IDH mutant, and 28 (39.4%) were diffuse astrocytomas IDH wild-type. Thirty-five (49.3%) patients were MGMT methylated. Median follow up was 144 months (range 23–180).
RESULTS
thirty-one patients (43.7%) underwent second surgery, 24 patients (33.8%) second-line chemotherapy (rechallenge with TMZ or nitrosoureas), and 16 patients (22.5%) radiotherapy with a median PFS of 58 months (IC 95% 49–116). The association between prognostic factors and type of salvage therapy revealed a prevalence of younger age (≤ 45 years), non-enhancing tumor and location in eloquent area among patients treated with second surgery or chemotherapy, while aolder age (> 45 years) and contrast-enhancing tumors prevailed among patients receiving radiotherapy. Overall, median PFS was 60 months after second surgery (IC95% 43–116) and chemotherapy (IC95% 51–69), and 38 months after radiotherapy (IC95% 15–64) (p 0.09). No significant benefit in length of PFS was achieved in oligodendrogliomas undergoing second surgery (60 months) as compared with oligodendrogliomas treated with radiation or chemotherapy (58 months, p 0.11). PFS of diffuse astrocytomas IDH wild-type following second surgery (53 months) did not differ from that of patients treated with adjuvant treatments (65 months, p 0.28). Overall, median OS from the first salvage therapy was 117 months (IC95% 93 - 123+): 120 months (IC95% 108–140+) after second surgery, 94 months (IC95% 75–117+) after chemotherapy, and 62 months (IC95% 27–112) after radiotherapy (p 0.04). Median OS (123 months, IC95% 106–154) was prolonged in oligodendrogliomas receiving second surgery as compared to those receiving radiotherapy or chemotherapy (93 months, IC 95% 61–112, p 0.07), while median OS in diffuse astrocytomas IDH wild-type did not differ between those who received second surgery or radiotherapy or chemotherapy.
CONCLUSION: W
hen feasible, reoperation as first salvage treatment following initial TMZ in grade II gliomas seems to offer a probability of a longer OS as compared with second-line chemotherapy or radiotherapy, and this could hold true especially for oligodendrogliomas.
Collapse
Affiliation(s)
- A Pellerino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - L Bello
- Department of Neurosurgery, Humanitas Hospital, Milan, Italy
| | - M Conti Nibali
- Department of Neurosurgery, Humanitas Hospital, Milan, Italy
| | - F Bruno
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Mo
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - E Pronello
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Franchino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Soffietti
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| |
Collapse
|
6
|
Bruno F, Pronello E, Bortolani S, Palmiero R, Melcarne A, Chiappella A, Mantovani C, Soffietti R, Rudà R. P14.85 Brain metastasis from Hodgkin’s Lymphoma: case report and literature review. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Central nervous system (CNS) metastases from Hodgkin’s Lymphoma (HL) are very rare, occurring in 0.02–0.5% of cases. They are usually associated to systemic relapse of the disease. Treatment options for HL brain metastases include surgery, radiotherapy, and systemic chemotherapy.
CASE REPORT
A 54 year-old woman presented with thoracic pain and dyspnea. Chest CT showed a thoracic bulky mass larger than 10 cm. Biopsy confirmed HL stage IIA, nodular sclerosing variant. No typical B symptoms, such as fever, night sweats or weight loss, were observed. The patient underwent chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD scheme), followed by 30Gy mediastinic radiotherapy (RT), which led to complete remission in September 2017. After 3 months, she presented with headache and rapidly progressing gait disorder. MRI showed a contrast-enhanced lesion in the right occipital lobe, with central necrosis and massive edema. Total-body CT scan and FDG-PET ruled out either the presence of new solid tumors or systemic relapses of HL. Gross total resection of the brain lesion was carried out, and HL histology was confirmed. CSF analysis from lumbar puncture was normal. Afterwards, the patient underwent 2 cycles of high dose cytarabine, but she rapidly progressed, and received salvage RT (30 Gy). Nevertheless, further systemic progression occurred: the patient developed headache, diplopia and dysphagia and, unfortunately, she died 6 months after the diagnosis of brain metastasis.
DISCUSSION
Thus far, only 45 cases of CNS HL have been reported from 2000 to 2018. Whole brain radiotherapy, with or without chemotherapy, was the most common treatment. In our patient, we chose surgical resection for the solitary brain metastasis followed by chemotherapy, delaying RT at recurrence. In the literature, median overall survival of patients diagnosed with brain metastases from HL is 18 months (1–273): 17 patients (38%) showed a progression (local / systemic: 12/17 - 71%), while 28 (62%) showed complete remission after a median follow-up of 20 months (6–273).
CONCLUSION
Intracranial localisation of Hodgkin’s Lymphoma is a rare entity but still has to be taken into account. Advanced brain imaging could be of help in case of uncertain radiological presentation. A multidisciplinary approach is needed as there is no consensus on the best treatment to choose: surgery, radiotherapy and chemotherapy should be considered on individual basis.
Collapse
Affiliation(s)
- F Bruno
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - E Pronello
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - S Bortolani
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Palmiero
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - A Melcarne
- Dept. of Neurosurgery, University and City of Health and Science Hospital, Turin, Italy
| | - A Chiappella
- Dept. of Haematology, University and City of Health and Science Hospital, Turin, Italy
| | - C Mantovani
- Dept. of Radiotherapy, University and City of Health and Science Hospital, Turin, Italy
| | - R Soffietti
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| |
Collapse
|
7
|
Villani V, Fabi A, Gaviani P, Rudà R, Lombardi G, Simonetti G, Silvani A, Pronello E, Minniti G, Pace A. P14.83 Adjuvant chemotherapy after severe myelotoxicity during temozolomide chemoradiation in gliomas. It is feasibile? The talian Multicentric Study (AINO). Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
BACKGROUND
Malignant gliomas are aggressive primitive brain tumor in adults. Today, the standard of care is Temozolomide (TMZ) administered daily with radiation therapy, followed by adjuvant TMZ. TMZ treatment has been considered to have a low toxicity profile. However, during concomitant treatment some patient may develop a severe myelosuppression. This toxicity may be in some cases prolonged and lead to treatment discontinuation.
MATERIAL AND METHODS
We have retrospectively collected data from 5 italian neuro-oncological centers, about glioma patients who developed severe and prolonged hematological toxicity during concomitant chemoradiotherapy with TMZ. The purpouse of this study is to evaluate: percentage of patients receiving adjuvant chemotherapy after severe myelotoxicity; rate of toxicity observed during adjuvant chemotherapy.
RESULTS
54 glioma patients who developed myelosuppression of grade 3 or 4 were considered. Hystology was Glioblastoma in 45 patients (83%); 63% of patients were female. Myelotoxicity during concomitant phase occurred at a median of 4 weeks (range 1–8) from the start of treatment.After recovery of myelotoxicity 19 patients did not received any treatment while 35 (65%) were treated with chemotherapy (28 received standard TMZ, one TMZ with metronomic schedule, 2 lomustine and 4 other agents). Among patients treated with TMZ, 13 patients presented hematological toxicity grade 3–4 which required treatment discontinuation in 7 cases (20%).
CONCLUSION
we observed that 80 % of glioma patients presenting severe myelotoxicity during concomitant radiochemotherapy may be treated with maintenance TMZ after blood value recovery.
Collapse
Affiliation(s)
| | | | - P Gaviani
- UO NEURO-ONCOLOGIA FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Milano, Italy
| | - R Rudà
- Department of Neuro-Oncology University of Turin and City of Health and Science Hospital, Torino, Italy
| | - G Lombardi
- Department of Experimental and Clinical Oncology Medical Oncology 1,Veneto Institute of Oncology-IRCCS, Padova, Italy
| | - G Simonetti
- UO NEURO-ONCOLOGIA FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Milano, Italy
| | - A Silvani
- UO NEURO-ONCOLOGIA FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Milano, Italy
| | - E Pronello
- Department of Neuro-Oncology University of Turin and City of Health and Science Hospital, Torino, Italy
| | | | | |
Collapse
|